Circulating miRNA Expression Profiles and Machine Learning Models in Association with Response to Irinotecan-Based Treatment in Metastatic Colorectal Cancer

被引:9
作者
Pliakou, Evangelia [1 ]
Lampropoulou, Dimitra Ioanna [2 ]
Dovrolis, Nikolas [3 ]
Chrysikos, Dimosthenis [4 ]
Filippou, Dimitrios [5 ]
Papadimitriou, Christos [6 ]
Vezakis, Antonios [7 ]
Aravantinos, Gerasimos [1 ]
Gazouli, Maria [8 ]
机构
[1] Gen Oncol Hosp Kifissia Agioi Anargiroi, Dept Med Oncol 2, Nea Kifissia, Athens 14564, Greece
[2] ECONCARE, Athens 11528, Greece
[3] Democritus Univ Thrace, Dept Med, Lab Biol, Alexandroupolis 68100, Greece
[4] Natl & Kapodistrian Univ Athens, Hippoctat Hosp, Med Sch, Dept Propaedeut Surg 1, Athens 11528, Greece
[5] Natl & Kapodistrian Univ Athens, Med Sch, Dept Anat, Athens 11527, Greece
[6] Natl & Kapodistrian Univ Athens, Aretaie Hosp, Med Sch, Dept Surg 2, Athens 11528, Greece
[7] Natl & Kapodistrian Univ Athens, Aretaie Univ Hosp, Med Sch, Dept Surg, Athens 11528, Greece
[8] Natl & Kapodistrian Univ Athens, Med Sch, Dept Basic Med Sci, Lab Biol, Athens 11527, Greece
关键词
microRNAs; colorectal cancer; machine learning; artificial intelligence; irinotecan; resistance; DOWN-REGULATION; GASTRIC-CANCER; CELLS; ANGIOGENESIS; BEVACIZUMAB; MANAGEMENT; ONCOLOGY; SURVIVAL; GROWTH;
D O I
10.3390/ijms24010046
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Colorectal cancer represents a leading cause of cancer-related morbidity and mortality. Despite improvements, chemotherapy remains the backbone of colorectal cancer treatment. The aim of this study is to investigate the variation of circulating microRNA expression profiles and the response to irinotecan-based treatment in metastatic colorectal cancer and to identify relevant target genes and molecular functions. Serum samples from 95 metastatic colorectal cancer patients were analyzed. The microRNA expression was tested with a NucleoSpin miRNA kit (Machnery-Nagel, Germany), and a machine learning approach was subsequently applied for microRNA profiling. The top 10 upregulated microRNAs in the non-responders group were hsa-miR-181b-5p, hsa-miR-10b-5p, hsa-let-7f-5p, hsa-miR-181a-5p, hsa-miR-181d-5p, hsa-miR-301a-3p, hsa-miR-92a-3p, hsa-miR-155-5p, hsa-miR-30c-5p, and hsa-let-7i-5p. Similarly, the top 10 downregulated microRNAs were hsa-let-7d-5p, hsa-let-7c-5p, hsa-miR-215-5p, hsa-miR-143-3p, hsa-let-7a-5p, hsa-miR-10a-5p, hsa-miR-142-5p, hsa-miR-148a-3p, hsa-miR-122-5p, and hsa-miR-17-5p. The upregulation of microRNAs in the miR-181 family and the downregulation of those in the let-7 family appear to be mostly involved with non-responsiveness to irinotecan-based treatment.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] Machine learning and experimental analyses identified miRNA expression models associated with metastatic osteosarcoma
    Abedi, Samira
    Behmanesh, Ali
    Mazhar, Farid Najd
    Bagherifard, Abolfazl
    Sami, Sam Hajialiloo
    Heidari, Negar
    Hossein-Khannazer, Nikoo
    Namazifard, Saina
    Arki, Mandana Kazem
    Shams, Roshanak
    Zarrabi, Ali
    Vosough, Massoud
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2024, 1870 (07):
  • [32] Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy
    Shitara, Kohei
    Yuki, Satoshi
    Yamazaki, Kentaro
    Naito, Yoichi
    Fukushima, Hiraku
    Komatsu, Yoshito
    Yasui, Hirofumi
    Takano, Toshimi
    Muro, Kei
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (04) : 595 - 603
  • [33] Patients with hMLH1 or/and hMSH2-deficient Metastatic Colorectal Cancer Are Associated with Reduced Levels of Vascular Endothelial Growth Factor-1 Expression and Higher Response Rate to Irinotecan-based Regimen
    Bendardaf, Riyad
    Sharif-Askari, Fatemeh Saheb
    Sharif-Askari, Narjes Saheb
    Syrjanen, Kari
    Pyrhonen, Seppo
    ANTICANCER RESEARCH, 2018, 38 (11) : 6399 - 6404
  • [34] Association of differential miRNA expression with hepatic vs. peritoneal metastatic spread in colorectal cancer
    Heublein, Sabine
    Albertsmeier, Markus
    Pfeifer, David
    Loehrs, Lisa
    Bazhin, Alexandr V.
    Kirchner, Thomas
    Werner, Jens
    Neumann, Jens
    Angele, Martin Kurt
    BMC CANCER, 2018, 18
  • [35] mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients
    Mostert, Bianca
    Sieuwerts, Anieta M.
    Bolt-de Vries, Joan
    Kraan, Jaco
    Lalmahomed, Zarina
    van Galen, Anne
    van der Spoel, Petra
    de Weerd, Vanja
    Ramirez-Moreno, Raquel
    Smid, Marcel
    Verhoef, Cornelis
    IJzermans, Jan N. M.
    Gratama, Jan W.
    Sleijfer, Stefan
    Foekens, John A.
    Martens, John W. M.
    MOLECULAR ONCOLOGY, 2015, 9 (04) : 920 - 932
  • [36] KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer
    Cabart, Mathilde
    Frenel, Jean-Sebastien
    Campion, Loic
    Ramee, Jean-Francois
    Dupuis, Olivier
    Senellart, Helene
    Hiret, Sandrine
    Douillard, Jean-Yves
    Bennouna, Jaafar
    BULLETIN DU CANCER, 2016, 103 (06) : 541 - 551
  • [37] Simplified Prognostic Model in Patients with Oxaliplatin-Based or Irinotecan-Based First-Line Chemotherapy for Metastatic Colorectal Cancer: A GERCOR Study
    Chibaudel, Benoist
    Bonnetain, Franck
    Tournigand, Christophe
    Bengrine-Lefevre, Leila
    Teixeira, Luis
    Artru, Pascal
    Desrame, Jerome
    Larsen, Annette K.
    Andre, Thierry
    Louvet, Christophe
    de Gramont, Aimery
    ONCOLOGIST, 2011, 16 (09) : 1228 - 1238
  • [38] A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients
    Toledano-Fonseca, M.
    Gomez-Espana, M. A.
    Elez, E.
    Gravalos, C.
    Garcia-Alfonso, P.
    Rodriguez, R.
    Losa, F.
    Diaz, I. Ales
    Grana, B.
    Valladares-Ayerbes, M.
    Garcia-Ortiz, M. V.
    Polo, E.
    Salgado, M.
    Rivera, F.
    Safont, M. J.
    Salud, A.
    Ruiz-Casado, A.
    Tabernero, J. M.
    Riesco, M. C.
    Rodriguez-Ariza, A.
    Aranda, E.
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 159
  • [39] Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer
    Suenaga, Mitsukuni
    Schirripa, Marta
    Cao, Shu
    Zhang, Wu
    Yang, Dongyun
    Cremolini, Chiara
    Lonardi, Sara
    Bergamo, Francesca
    Ning, Yang
    Yamamoto, Noriko
    Okazaki, Satoshi
    Berger, Martin D.
    Miyamoto, Yuji
    Gopez, Roel, Jr.
    Barzi, Afsaneh
    Yamaguchi, Toshiharu
    Stintzing, Sebastian
    Heinemann, Volker
    Loupakis, Fotios
    Falcone, Alfredo
    Lenz, Heinz-Josef
    PHARMACOGENOMICS JOURNAL, 2018, 18 (05) : 623 - 632
  • [40] Long non-coding RNA polymorphisms and prediction of response to chemotherapy based on irinotecan in patients with metastatic colorectal cancer
    Lampropoulou, Dimitra-Ioanna
    Aravantinos, Gerasimos
    Katifelis, Hector
    Lazaris, Foivos
    Laschos, Konstantinos
    Theodosopoulos, Theodosios
    Papadimitriou, Christos
    Gazouli, Maria
    CANCER BIOMARKERS, 2019, 25 (02) : 213 - 221